Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Italy’s Recordati Starts $50 Million Greenfield Investment In Turkey

This article was originally published in PharmAsia News

Executive Summary

Italian pharmaceutical company Recordati invests $50 million in Turkey to establish a production facility in Tekirdag province to produce cardiovascular drugs.

You may also be interested in...



What Pricing Pressure? Recordati Continues Push Into Turkey With Latest Acquisition

Although many pharma companies are reducing investments in Turkey after a series of controversial government price cuts, Italian drug maker Recordati S.p.A is doing just the opposite, buying Istanbul-based Dr. F. Frick Ilac for $130 million earlier this month, its second acquisition in Turkey in three years. Recordati, in fact, sees significant growth opportunities in Turkey and Eastern European, and says more deals could be on the way

Turkey’s $2.6Bn Hospital Medtech Debts Create Problems On Top Of COVID-19

Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.

COVID-19 Pushes Ongoing Concerns of Turkish Medtech Industry Down The Agenda

The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel